November 10, 2006: FDA Approves Mirapex for Restless Legs Syndrome
Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). RLS is a condition that causes unpleasant sensations, discomfort, and restlessness in the legs. Click here to read the press release from Boehringer Ingelheim.
August 23, 2006: Texas Woman Alleges that Mirapex Made Her a Compulsive Gambler
A lawsuit has been brought in Texas state court by a bank director from Texas, who alleges that Mirapex caused her to become a compulsive gambler, resulting in the loss of $200,000 in less than a year. The plaintiff sued Mirapex-manufacturer Pfizer Pharmaceuticals and distributor Boehringer Ingelheim Pharmaceuticals, Inc., for failing to warn doctors and patients of the risk of compulsive behavior by Mirapex users. A claim was also filed against the plaintiff's physician for failing to monitor her behavior while taking Mirapex.
June 2006: Mirapex Use Possibly Linked to Compulsive Behavior
There have been recent reports of Parkinson's disease and Restless Leg Syndrome (RLS) patients experiencing strange, out-of-control, compulsive urges while being treated with Mirapex or other "dopamine agonist" medicines. Among the strange behaviors that have been reported are cases of pathological gambling, hypersexuality (increased sexual thoughts, feelings, or behavior), and compulsive eating. Mirapex's prescribing information has been changed to describe these reported cases. Mirapex's prescribing information states that the incidence of compulsive behavior has been low, and that the behavior is generally reversible upon dose reduction or treatment discontinuation. The suggested link between Mirapex use and compulsive behavior is still under examination.